Lenvatinib is a multi-target tyrosine kinase inhibitor mainly used for the treatment of malignant tumors such as thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma, with significant anti-tumor effects and clinical advantages.

1. Main indications

(1) Differentiated thyroid cancer: Used for cases of refractory local recurrence or metastasis caused by radioactive iodine, it can significantly prolong progression free survival.

(2) Hepatocellular carcinoma: first-line treatment for unresectable advanced liver cancer patients has a better objective response rate than sorafenib.

(3) Renal cell carcinoma: Combination therapy with everolimus improves treatment outcomes in advanced cases that have previously received anti angiogenic therapy.

2 therapeutic effects

(1) Liver cancer efficacy: The REFELECT study showed a median overall survival of 13.6 months and an objective response rate of 24%.

(2) Thyroid cancer: can reduce the risk of disease progression by 79%, with a median progression free survival of 18.3 months.

(3) Combination therapy for renal cancer: The median progression free survival with everolimus is 14.6 months, which is superior to monotherapy.

3 mechanisms of action

(1) Target inhibition: Selective inhibition of receptors such as VEGFR1-3, FGFR1-4, PDGFR α, etc., blocking multiple signaling pathways.

(2) Anti angiogenesis: By inhibiting the VEGF signaling pathway, it effectively reduces tumor angiogenesis.

(3) Direct anti-tumor effect: inhibits tumor cell proliferation and metastasis, exerting multiple anti-tumor effects.

4 Clinical advantages

(1) Combination immunotherapy: Combined with PD-1 inhibitors can significantly enhance the efficacy of immunotherapy.

(2) Medication convenience: once daily oral dosing regimen to improve patient compliance.

(3) Good tolerance: Common adverse reactions are controllable, and most patients can maintain treatment for a long time.